CAPR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CAPR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capricor Therapeutics's other current assets for the quarter that ended in Mar. 2024 was $1.13 Mil.
Capricor Therapeutics's quarterly other current assets increased from Sep. 2023 ($0.46 Mil) to Dec. 2023 ($0.99 Mil) and increased from Dec. 2023 ($0.99 Mil) to Mar. 2024 ($1.13Mil).
Capricor Therapeutics's annual other current assets declined from Dec. 2021 ($1.16 Mil) to Dec. 2022 ($0.92 Mil) increased from Dec. 2022 ($0.92 Mil) to Dec. 2023 ($0.99 Mil).
The historical data trend for Capricor Therapeutics's Other Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capricor Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Other Current Assets | Get a 7-Day Free Trial | 0.57 | 1.01 | 1.16 | 0.92 | 0.99 |
Capricor Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Other Current Assets | Get a 7-Day Free Trial | 0.88 | 0.58 | 0.46 | 0.99 | 1.13 |
Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:
The assets grouped under other current assets are most commonly:
Some companies can and do choose to report each of these items separately.
Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.
Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.
Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.
Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.
There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.
At most companies, other current assets are a small and unimportant part of the total balance sheet.
Thank you for viewing the detailed overview of Capricor Therapeutics's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
David B Musket | director | C/O CONOR MEDSYSTEMS, INC., 1003 HAMILTON COURT, MENLO PARK CA 94025 |
Collier Earl M Jr | director | C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
Paul Gisbert Auwaerter | director | C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121 |
Mike Kelliher | director | C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121 |
Philip J Gotwals | director | C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121 |
Xavier Avat | officer: CHIEF BUSINESS OFFICER | 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121 |
Karimah Es Sabar | director | C/O 8840 WILSHIRE BOULEVARD, 2ND FLOOR, BEVERLY HILLS CA 90211 |
Linda Marban | director, officer: CHIEF EXECUTIVE OFFICER | C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211 |
Dunbar George W Jr | director | C/O COMPETITIVE TECHNOLOGIES, INC., 777 COMMERCE DRIVE, SUITE 100, FAIRFIELD CT 06825 |
Karen Krasney | officer: EVP, GENERAL COUNSEL | C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211 |
Anthony Bergmann | officer: CHIEF FINANCIAL OFFICER | C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211 |
Louis Manzo | director | C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211 |
Cedars Sinai Medical Center | 10 percent owner | 8700 BEVERLY BLVD, LOS ANGELES CA 90048-1865 |
St. John Edward A. | 10 percent owner | 2560 LORD BALTIMORE DRIVE, BALTIMORE MD 21244 |
Leland Gershell | officer: Chief Financial Officer | C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., STE 306, NEW YORK NY 10022 |
From GuruFocus
By sperokesalga sperokesalga • 03-02-2023
By Marketwired • 09-06-2023
By GuruFocusNews GuruFocusNews • 07-07-2022
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 10-19-2023
By Marketwired • 09-29-2023
By Marketwired • 08-07-2023
By Stock market mentor Stock market mentor • 01-12-2023
By Marketwired • 07-24-2023
By Stock market mentor Stock market mentor • 01-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.